Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INO-4600
- Development stage
- Unknown
- Lead developer
- Inovio Pharmaceuticals
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
INO-4600 is a synthetic DNA (synDNA) vaccine candidate developed by Inovio Pharmaceuticals in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for the prevention of smallpox (Variola virus). Utilizing Inovio's proprietary SynCon technology, the vaccine consists of DNA plasmids designed to encode consensus sequences of key viral antigens, specifically L1, A27, B5, and A33. Upon administration via intramuscular injection followed by electroporation using the CELLECTRA delivery system, the plasmids enter host cells and express the targeted antigens. This process elicits a robust immune response characterized by both neutralizing antibodies and T-cell mediated immunity. INO-4600 is designed as a non-replicating, stable alternative to traditional live-attenuated smallpox vaccines, offering a potentially safer profile for immunocompromised individuals and improved logistics for biodefense stockpiling due to its thermal stability.
- Other names
- synDNA smallpox vaccineInovio smallpox vaccineDNA smallpox vaccine
02
Targets
A27 (Orthopoxvirus A27 protein)B5R (Vaccinia virus extracellular enveloped virion protein B5)HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)
Beyond the preview
Go deeper on INO-4600.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INO-4600.